B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?

The COVID-19 pandemic has presented several challenges due to insufficient evidence to guide clinical practice. Many patients with severe, refractory rheumatic disease (including vasculitis, systemic lupus erythematosus (SLE), and rheumatoid arthritis) depend on B-cell depletion with anti-CD20 monoclonal antibodies, such as rituximab. In the current crisis, some clinicians and patients have…

Read the full article here

Related Articles